Bleomycin-induced flagellate dermatitis
Flagellate pigmentation represents a unique adverse effect of bleomycin therapy that is encountered in 8-22% of patients. But this occurrence is independent of dose, route of administration, and underlying disorder (including type of malignancy). We highlight a case of a middle-aged man who develope...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Wolters Kluwer Medknow Publications,
2020-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Flagellate pigmentation represents a unique adverse effect of bleomycin therapy that is encountered in 8-22% of patients. But this occurrence is independent of dose, route of administration, and underlying disorder (including type of malignancy). We highlight a case of a middle-aged man who developed flagellate hyperpigmentation following bleomycin-containing combined chemotherapy for Hodgkin's lymphoma. Early recognition of bleomycin as the culprit drug is of paramount importance as these patients are usually on multiple medications. |
|---|---|
| Item Description: | 2349-5847 2349-5782 10.4103/Pigmentinternational.Pigmentinternational_12_20 |